| FORM 990 PART I, LINE 1 & PART III, LINE 1 |
THE MASSACHUSETTS EYE AND EAR INFIRMARY ("THE INFIRMARY") IS A NOT-FOR-PROFIT TEACHING HOSPITAL CONDUCTING PATIENT CARE AND RESEARCH. THE INFIRMARY IS A TEACHING HOSPITAL OF HARVARD MEDICAL SCHOOL AND AN INTERNATIONAL CENTER FOR RESEARCH. IT HAS THE MOST COMPETITIVE PROGRAM IN THE COUNTRY FOR EYE, EAR, NOSE, AND THROAT RESIDENCY TRAINING AND THE WORLD'S LARGEST OPHTHALMIC FELLOWSHIP PROGRAM. IT IS PART OF A SYSTEM OF RELATED ENTITIES THAT PROVIDE SPECIALIZED MEDICAL CARE COLLECTIVELY KNOWN AS "MASSACHUSETTS EYE AND EAR INFIRMARY" ("MEEI"). FORM 990, PART III, LINE 4A: Massachusetts Eye and Ear is a specialty hospital dedicated to excellence in the care of disorders that affect the eye, ear, nose, throat and adjacent regions of the head and neck. World-renowned for care, research and teaching in these areas of expertise, Mass. Eye and Ear physicians and scientists are driven by a mission to find cures for blindness and deafness. In the 2018-2019 "Best Hospitals Survey," U.S. News & World Report again ranked Mass. Eye and Ear a top hospital in the nation: #4 for eye care and #6 for ear, nose and throat care. The commitment to provide compassionate and accessible patient care continued with the expansion to twenty clinical care locations in Massachusetts and Rhode Island. In 2018 Mass. Eye and Ear became a proud member of the Partners HealthCare system. This integration has and will continue to allow for a more seamless sharing of some of the centralized services Partners extends to its entities, including PeopleSoft (enterprise resource planning) and Epic (unified patient care system). CLINICAL HIGHLIGHTS DEPARTMENT OF OPHTHALMOLOGY - FACULTY HIRES Paolo Bispo, PhD Yihe Chen, MD Deborah Jacobs, MD Lynette Johns, OD Patrick Lee, OD Courtney Ondeck, MD, MPhil Elizabeth Rossin, MD, PhD Bart Chwalisz, MD (part-time) David Sola-Del Valle, MD Allison Soneru, MD Aisha Traish, MD Tav van Zyl, MD Nazlee Zebardast, MD, MSc Department of Ophthalmology - Faculty Appointments Professor of Ophthalmology Eric Pierce, MD, PhD: William F. Chatlos Professor of Ophthalmology Associate Professor of Ophthalmology Dean Cestari, MD Jack Greiner, MS, OD, DO, PhD (Part-time) Tatjana Jakobs, MD George Papaliodis, MD Luk Vandenberghe, PhD Mary Aronow, MD Assistant Professor of Ophthalmology Petr Baranov, MD, PhD Jason Comander, MD, PhD Tobias Elze, PhD Kevin Houston, OD, MSc Charles Leahy, OD, MS (Part-time) John B. Miller, MD Ayellet Segr, MSc, PhD Brian Song, MD Yoshihiro Yonekawa, MD Instructor in Ophthalmology Paulo Bispo, PhD Yihe Chen, MD Department of Otolaryngology - Faculty Hires Full-time Medical Staff Dunia E. Abdul-Aziz, MD Craig A. Jones, MD Matthew R. Naunheim, MD Michael D. Otremba, MD Research Faculty Daniel L. Faden, MD Srinivas Vinod Saladi, PhD Community-based Medical Staff Pamela S. Jones, MD Vishnu Kannabiran, MD Geoffrey E. Leber, MD, FACS George A. Scangas, MD Department of Otolaryngology - Faculty Appointments Professor Mark A. Varvares, MD Associate Professor Stacey T. Gray, MD Kristina Simonyan, MD, PhD, Dr med Assistant Professor Alicia M. Quesnel, MD Anne E. Takesian, PhD Department of Otolaryngology - Other Promotions/New Leadership Jean Bruch, DMD, MD, was named director of the Norman Knight Hyperbaric Medicine Center Nate Jowett, MD, FRCSC, was named director of the Surgical Photonics and Engineering Laboratory Faisal Karmali, PhD, and Richard F. Lewis, MD, were named co-directors of the Jenks Vestibular Physiology Laboratory Konstantina M. Stankovic, MD, PhD, FACS, was promoted to director of the Division of Otology and Neurotology Department of Anesthesiology - Faculty Hires Melina Hutchison, CRNA Timothy Riley, CRNA Department of Anesthesiology - Faculty Promotions Alvaro Andres Macias, MD: Associate Clinical Director; Assistant Professor, Active Staff Mass Eye and Ear Iuliu Fat, MD: Associate Medical Director for Preoperative Evaluation and Testing; Associate Anesthesiologist, Active Staff, Mass Eye and Ear Gustavo Lozada, MD, MMED: Co-Director of Ambulatory Anesthesia Nancy Gessner, MD: Anesthesiologist, Active Staff, Mass Eye and Ear Maria Bortkiewicz, MD: Anesthesiologist, Active Staff, Mass Eye and Ear Susanna Panitsas, MD: Associate Anesthesiologist, Active Staff, Mass Eye and Ear Benjamin Mizell, MD: Associate Anesthesiologist, Active Staff, Mass Eye and Ear Kathrin Bourdeu, MD: Associate Anesthesiologist, Active Staff, Mass Eye and Ear Artem Grush, MD: Anesthesiologist, Active Staff, Mass Eye and Ear Nita Sahani, MBBS: Associate Anesthesiologist, Active Staff, Mass Eye and Ear Yana Levin, MD: Associate Anesthesiologist, Active Staff, Mass Eye and Ear Department of Radiology For FY18, the Department of Radiology had a total of 160 resident and fellow rotations joining Dr. Curtin and faculty for daily read out sessions and head and neck imaging training (44 from MGH, 49 from BWH, and 67 from BIDMC). |
| RESEARCH HIGHLIGHTS |
Department of Ophthalmology AMD Center of Excellence Researchers Identify Potential Blood Markers for Age-Related Macular Degeneration Research conducted by a team of Mass. Eye and Ear investigators showed that metabolomics can be used to identify potential blood biomarkers for AMD, including its severity stages. Metabolomics is the study of circulating metabolites in our body that reflect our genes and the effect of the environment and, therefore, are thought to closely represent the true functional state of complex diseases, including AMD. In collaboration with the University of Coimbra and colleagues at the Channing Division of Network Medicine of Brigham and Women's Hospital, the researchers-including Deeba Husain, MD, and Joan W. Miller, MD-studied blood samples from 90 patients with AMD and identified 87 metabolites that were significantly different when compared to those without AMD. They also note varying characteristics among the blood profiles at each stage of the disease. The most significant metabolites are involved in lipid metabolism, particularly via the glycerophospholipid pathway. This work supports research suggesting that lipids may be involved in the pathogenesis of AMD, although the exact role of lipids in the disease process remains unclear. The results from this study indicate that metabolomics profiling may provide novel insights into the relationship between lipids and AMD. These findings may lead to earlier diagnosis and better prognostic information for patients, and, potentially, new targets for AMD treatment. Cornea Center of Excellence New Strategy May Help Promote Corneal Allograft Survival Mass. Eye and Ear researchers led by senior author Reza Dana, MD, MPH, MSc, have developed a potential new strategy for improving outcomes in corneal transplant surgeries by injecting vasoactive intestinal peptide (VIP) into the eye. The team reports for the first time that injection of the neuropeptide VIP directly into the eyes of mice enhanced corneal graft survival. The study shows that VIP produced other benefits, including acceleration of endothelial wound closure, protection of corneal endothelial cells (CEnCs), and improved corneal graft clarity. If proven successful in clinical studies, this novel approach may help alleviate vision loss in many patients with corneal disease. Diabetic Eye Disease Center of Excellence Imaging May Offer New Insights into Disease Progression of Diabetic Choroidopathy According to a study led by John B. Miller, MD new imaging modalities, such as swept source optical coherence tomography (SS-OCT), may help researchers understand how the choroidal vasculature contributes to diabetic eye disease. The cross-sectional study used SS-OCT, a novel OCT device that enables imaging the choroid with better resolution, and studied patients with different stages of diabetic retinopathy. Choroidal vascular density (CVD) and choroidal vascular volume (CVV) were introduced as new quantitative parameters to assess the choroidal vasculature. Study results demonstrated that diabetic eyes with diabetic macular edema or proliferative diabetic retinopathy (PDR) demonstrated a reduced CVD, as compared to controls. Additionally, eyes with PDR also demonstrated reduced CVV. These results suggest that vascular abnormalities accumulate with the severity of diabetic retinopathy. This study also emphasizes that a diabetic choroidopathy (i.e. changes in the choroidal vasculature) probably occurs simultaneously with changes in the retinal vasculature, even though it is still not clear if this is a primary or secondary event. Elucidating the relationship between diabetic choroidopathy and retinopathy is essential for a more complete understanding of diabetic eye disease, and to improve its prognosis and treatment. Glaucoma Center of Excellence Infectious Disease Institute Researchers Discover New Class of Antibiotics to Fight Leading Superbugs In a significant advance against drug-resistant superbugs, investigators supported by the Harvard-wide Program on Antibiotic Resistance identified a new class of synthetic antibiotics that have been shown to be effective against Staphylococcus aureus and Enterococcus. These two pathogens are among the most virulent, multi-drug resistant pathogens and are responsible for thousands of deaths each year. The pioneering work by this multidisciplinary group of researchers-including Michael Gilmore, PhD, founder and director of the Harvard-wide consortium that includes collaborators from Mass. Eye and Ear, Harvard Medical School, Mass General Hospital, and Brown University-could one day help treat deadly infections caused by these superbugs. Systemic Therapy Outperforms Intraocular Implant for Treating Uveitis For patients with uveitis, systemic therapy consisting of corticosteroids and immunosuppressants preserved vision better, and had fewer adverse outcomes, than a long-lasting corticosteroid intraocular implant, according to a clinical trial funded by the National Eye Institute (NEI). According to Writing Committee Chair and Mass. Eye and Ear researcher, John Kempen, MD, PhD, the results are meaningful not only to ophthalmology but to the broader field of medicine given that inflammatory diseases affect many different organs; these results indicated that systemic therapy as administered in the study had a favorable safety profile. Concerns about potential adverse effects of systemic corticosteroid and immunosuppressive therapy drove the development of an intraocular implant to treat uveitis locally. As a result, the Multicenter Uveitis Steroid Treatment (MUST) trial was undertaken to evaluate whether the implant treatment was an improvement over systemic therapy for management of uveitis. These findings offer guidance to clinicians and patients in making informed decisions about uveitis treatment. Specifically, there is good evidence that systemic therapy would be the first choice of treatment for the average patients with intermediate, posterior, or panuveitis. The implant is effective in treating patients where systemic therapy fails to control inflammation or when patients cannot tolerate the oral medications. The duration of control of inflammation following implant treatment was approximately five years, much longer than expected. Mobility Enhancement and Vision Rehabilitation Center of Excellence Ocular Genomics Institute Genetic Variants May Predict Glaucoma Risk Researchers from Mass. Eye and Ear - including co-senior author Janey Wiggs, MD, PhD together with colleagues at King's College London, and University College London- have identified 133 genetic variants that may predict a person's risk of developing glaucoma. The research team studied 140,000 people drawn from two large patient research databases, UK Biobank and EPIC-Norfolk. They compared the DNA analysis and eye pressure readings of each patient to assess their likelihood of developing glaucoma. The team identified 133 genetic variants in the DNA of people who had high eye pressure readings, and thus had the highest risk of developing glaucoma. Using data from the NEIGHBORHOOD Consortium, they found that these genetic variations were able to predict whether someone might develop glaucoma with 75 percent accuracy. Their findings could lead to a genetic-based screening program that could provide faster and more accurate diagnoses. |
| Other Research |
Microglia protect sensory cells needed for vision after retinal detachment A research team led by senior author Kip Connor, PhD, has shown that microglia, the primary immune cells of the brain and retina, play a protective role in response to retinal detachment. Retinal detachment and subsequent degeneration of the retina can lead to progressive visual decline due to photoreceptor cell death, the major light-sensing cell in the eye. The researchers describe, for the first time, the beneficial role of microglial cells in the eye after retinal detachment - migrating to the site of injury to protect photoreceptors and to regulate local inflammation. Department of Otolaryngology Basic Science Researchers use optogenetics to transform cells in the ear to respond to light A Mass. Eye and Ear research team has shown that cells in the inner ear can become photoactive through the use of optogenetics, opening the door for a new generation of hearing devices that can be stimulated more precisely using laser light. In a report published in Molecular Therapy, the researchers describe successfully delivering light-sensitive microbial proteins (known as "opsins") to the cochlea. By changing the properties of these cells to react to laser light, the researchers hope that the technology accelerates the development of a new kind of cochlear implant that's performance is closer to natural hearing. While today's cochlear implants have restored hearing to more than 320,000 people, hearing through a cochlear implant is different from normal hearing. This is because current technology relies on a series of electrodes implanted in the fluid-filled inner ear that receive information from an external sound processor and microphone and sends that information to the cochlear nerve, and to the brain. The electrical current generated by the electrodes can be difficult to focus, especially in a conducting medium of fluid. Unlike electricity, using optogenetics to stimulate cells in the inner ear with laser light may offer a more focused beam that restricts the path of light to the hundreds of cells that are photoactive. Invasive cells in head and neck tumors predict cancer spread Head and neck tumors that contain cells undergoing a partial epithelial-to-mesenchymal transition - which transforms them from neatly organized blocks into irregular structures that extrude into the surrounding environment - are more likely to invade and spread to other parts of the body, according to a study led by researchers from Mass. Eye and Ear, Massachusetts General Hospital (MGH), and the Broad Institute of MIT and Harvard. In a report published in Cell, the researchers created the first atlas of head and neck cancer, revealing the many different kinds of cells, cancerous and non-cancerous, in primary head and neck tumors and their metastases. The findings provide important clues as to how head and neck cancers metastasize, and may have implications for other common cancers as well. Using a process known as single-cell RNA-sequencing, the researchers analyzed more than 6,000 individual cells from head and neck squamous cell carcinomas - the most common head and neck tumor. Through their analysis, the research team was able to characterize a unique structural transition involving cancer cells and normal cells in their environment that allows tumors to spread. Synaptopathy in the aging cochlea A fairly universal communication problem for middle aged and older listeners is an increasing difficulty understanding speech in noisy conditions. The discovery by Mass. Eye and Ear investigators in 2009 of dramatic age- and noise exposure-related cochlear synaptopathy, i.e., the loss of synaptic connections between the inner hair cell and the auditory nerve fibers that carry their information toward the brain, has suggested a possible contributor to these performance declines. In a recent study funded by the Department of Defense and published in the Journal of Neuroscience, researcher Sharon G. Kujawa, PhD, used a combination of electrophysiologic, pharmacologic, and histologic techniques to show evidence for temporal coding abnormalities that are present at the earliest stages of the auditory neural pathway. These deficits in representation of fast timing cues that are essential for speech-in-noise processing are highly correlated with the age-progressive loss of cochlear synapses and are largest at higher sound levels relevant to real world communication. Although the standard clinical audiogram is silent to this synaptic loss, the additional, noninvasive tests used in these studies could be adapted for future diagnostic approaches to assess "hidden" hearing loss in a clinical setting. Sensory overamplification in layer 5 auditory corticofugal projection neurons following cochlear nerve synaptic damage Layer 5 (L5) cortical projection neurons innervate far-ranging brain areas to coordinate integrative sensory processing and adaptive behaviors. In a study led by Daniel B. Polley, PhD, a plasticity in L5 auditory cortex (ACtx) neurons that innervate the inferior colliculus (IC), thalamus, lateral amygdala, and striatum were categorized. The research team tracked daily changes in sound processing using chronic wide-field calcium imaging of L5 axon terminals on the dorsal cap of the IC in awake, adult mice. Sound level growth functions at the level of the auditory nerve and corticocollicular axon terminals are both strongly depressed hours after noise-induced damage of cochlear afferent synapses. Corticocollicular response gain rebounded above baseline levels by the following day and remained elevated for several weeks despite a persistent reduction in auditory nerve input. Sustained potentiation of excitatory ACtx projection neurons that innervate multiple limbic and subcortical auditory centers may underlie hyperexcitability and aberrant functional coupling of distributed brain networks in tinnitus and hyperacusis. An engineering model to test for sensory reweighting Quantitative animal models are critically needed to provide proof of concept for the investigation of rehabilitative balance therapies (e.g., invasive vestibular prostheses) and treatment response prior to, or in conjunction with, human clinical trials. In a study led by Richard F. Lewis, MD, a novel approach to modeling the nonhuman primate postural control system is described. Previously, system identification methodologies and models were only used to describe human posture. However, using pseudorandom, roll-tilt balance platform stimuli to perturb the posture of a rhesus monkey in normal and mild vestibular (equilibrium) loss states, the researchers found that the relationship between trunk sway and platform roll-tilt was determined via stimulus-response curves and transfer function results. When a feedback controller model was used to explore sensory reweighting (i.e., changes in sensory reliance), it prevented the subject from falling off the tilting platform. This first-phase effort to model the balance control system in nonhuman primates is essential for future investigations toward the effects of invasive rehabilitative (balance) technologies on postural control. The neuroregenerative capacity of olfactory stem cells is not limitless: Implications for aging It's estimated that more than 60 percent of people between the ages of 65 and 80 have olfactory (smell) impairment. Not only is this a hazard in the inability to detect smoke from a fire, natural gas leaks in the home, or spoiled food, but it also significantly impacts quality of life and appreciation of food flavor. It's known that loss of olfactory neurons occurs with age, but our understanding of what causes this has been limited. In collaboration with Tufts University School of Medicine, Eric H. Holbrook, MD, developed a mouse model that displays a nasal olfactory membrane, which mimics what is found in human tissue. In this model, mice undergo rapid loss of the olfactory neurons, which causes the underlying immediate precursor stem cells to increase cell division and regenerate dying neurons at a high rate. Through this, the research team found that these cells have a limited capacity under such conditions and eventually disappear, leaving a membrane without neurons. However, a population of reserve basal stem cells remains, but are stuck in an inactive state. Experimental activation of these basal stem cells in mice has been shown to result in regeneration of new neurons and forms the basis of potential therapeutic treatments in human smell loss. |
| CRISPR therapy preserves hearing in progressive deafness model |
In collaboration with the Broad Institute of MIT and Harvard, Harvard University, and Howard Hughes Medical Institute, Zheng-Yi Chen, PhD, developed a CRISPR-Cas9 genome-editing therapy to prevent hearing loss in a mouse model of human genetic progressive deafness. The therapy delivers a CRISPR-Cas9 gene-editing protein complex directly into the sound-sensing hair cells via lipid rafts to disrupt an autosomal dominant mutation that would otherwise cause the cells to die. The researchers tested the method in a mouse model of progressive hearing loss with a mutated Tmc1 gene. The team injected the gene-editing mix into the cochlea of newborn mice genetically destined for profound hearing loss. The treated mice maintained a substantial amount of their hearing compared to the untreated mice. At four weeks, the untreated mice had a measurable response in their brainstem to sound starting at roughly 80 decibels, the volume of a garbage disposal or a loud radio. But the treated mice responded to sound starting around 65 decibels-approximately the same volume as a typical spoken conversation. Physiological measurements showed that the hair cells survived at a higher rate in the treated cochlea. At eight weeks, treated mice also retained their instinctive physical "startle" response to sudden loud sound, while the untreated mice did not respond. The work represents a significant step toward genome-editing to halt progression of genetic hearing loss. Delivering the Cas9 protein itself locally, instead of DNA elements that the cell can use to build Cas9, improved the DNA specificity and potential safety of the treatment. Cochlear amplification and tuning depend on the cellular arrangement within the organ of Corti The field of cochlear mechanics has been undergoing a revolution due to recent findings made possible by advancements in measurement techniques. While it has long been assumed that basilar-membrane (BM) motion is the most important determinant of sound transduction by the inner hair cells (IHCs), a recent study led by Sunil Puria, PhD, showed that other parts of the sensory epithelium close to the IHCs, such as the reticular lamina (RL), move with significantly greater amplitude for weaker sounds. With a computational-model of the mouse cochlea, the researchers showed that individual outer hair cells (OHCs) can work together to produce high hearing sensitivity and frequent selectivity because of the overlapping asymmetrical Y-shaped structures that they form with the Deiters' cells (DCs) and phalangeal processes (PhPs). Altering the geometry and material properties of these structures reveals that all three components have a profound effect on BM and reticular-lamina amplification and tuning. These results imply that the DCs and PhPs must be properly accounted for in emerging OHC regeneration therapies. Autologous platelet-rich plasma (PRP) for treatment of androgenic alopecia Platelet-rich plasma (PRP) is a minimally invasive, office-based procedure that uses autologous growth factors from a standard venipuncture to stimulate hair growth in patients with androgenic alopecia (AGA). Although PRP is commonly used to treat orthopedic issues and burn injuries, it is still a relatively novel technique for treatment of androgenic alopecia. A team of researchers, including Linda N. Lee, MD, Jenny X. Chen, MD, and Natalie Justicz, MD, performed a systematic review of the literature to examine the use and efficacy of PRP for AGA. The results of the study demonstrated PRP is a low-risk intervention that is associated with high patient satisfaction and objective improvements in multiple outcome measurements. The study revealed a range of techniques and protocols, highlighting the need for further research to standardize delivery methods and clinical outcome measurements. Mass. Eye and Ear is currently one of the only academic centers in the Northeast to perform and study this technique, both as a stand-alone procedure for androgenic alopecia and as an adjunct to hair transplantation surgeries. Currently, additional prospective studies for PRP are ongoing. Mifepristone may halt growth of intracranial tumor that causes hearing loss A team of researchers including Konstantina Stankovic, MD, PhD, FACS, has identified mifepristone, an FDA-approved drug for chemical abortion, as a promising candidate for the treatment of vestibular schwannoma, a sometimes-lethal tumor associated with neurofibromatosis 2 (NF2) or occurring sporadically. Currently, there are no FDA-approved drugs for vestibular schwannomas or the associated hearing loss. Therefore, patients with symptomatic or growing vestibular schwannomas often undergo surgical resection (through craniotomy) or radiation therapy, but both come with significant risks. In this study, the researchers performed the largest meta-analysis of the vestibular schwannoma transcriptome by studying 80 tumors from patients with sporadic and NF2-associated vestibular schwannomas. Then, through a survey of more than 1,100 drug candidates (all FDA-approved), they identified a short list of drugs likely to convert the abnormal transcriptional signature of a tumor to a more normal one. They tested eight of the most promising candidate drugs against cells grown from other human vestibular schwannomas and found mifepristone to be the most effective. Treatment of vestibular schwannoma cells with mifepristone reduced their proliferation rate by 80 percent. This represents the first application of algorithm-based repositioning of FDA-approved drugs for this tumor class. The study authors are cautiously optimistic about the therapeutic potential of mifepristone for patients with vestibular schwannoma and hope to begin a phase II clinical trial soon to determine efficacy of the drug for this indication. Clinical Practice Opioid prescription patterns after rhinoplasty surgery Facial plastic surgeons, including David A. Shaye, MD, MPH, Linda N. Lee, MD, and Rosh Sethi, MD, MPH, performed a study of 173 rhinoplasty patients over a one-year period to examine opioid prescription patterns using the Massachusetts opioid registry. The study showed a near-negligible rate of refills were required after surgery and 11.3 percent of patients never filled their opioid prescription at all. Recently published in JAMA Facial Plastic Surgery, the results suggest patients experience less pain than expected and that the optimal number of opioid tablets to manage postoperative rhinoplasty pain may be lower than expected. A reduction in narcotic prescriptions after rhinoplasty may limit the opportunity for opioid abuse, an epidemic in the United States, where less than five percent of the world's population consumes two-thirds of the world's opioid supply. As a result of their findings, the authors have reduced the number of opioid tablets they prescribe to patients by at least 50 percent. |
| NEWS HIGHLIGHTS |
Department of Ophthalmology In March Mass. Eye and Ear made medical history by performing the first FDA-approved LuxturnaT gene therapy procedure on a patient with inherited blindness. This is the first time any FDA-approved gene therapy has been given to a patient for any inherited disease. The treatment was developed by Spark Therapeutics and approved in December, 2017 by the Food and Drug Administration (FDA) for patients aged 12 months and older. Luxturna has been shown to improve visual function in children and adults with inherited retinal disease caused by mutations in the gene RPE65 for LCA inherited blindness. The landmark procedure was performed by Jason Comander MD, PhD, Associate Director of the Inherited Retinal Disorders Service at Mass. Eye and Ear in Boston. Several groups initiated clinical development, but special mention should be made of the team led by Dr. Jean Bennett at University of Pennsylvania. Mass. Eye and Ear has led the ophthalmology community in the development of outcome measures for ophthalmology, consistently publishing these measures since 2010 in a Quality and Outcomes Report. The department was also among the first to contribute electronic health record data to the American Academy of Ophthalmology's IRIS Registry (Intelligent Research in Sight). As one of five academic groups awarded unique access to the American Academy of Ophthalmology's IRIS Registry, Mass. Eye and Ear is now at the forefront of working with big data for quality improvement and monitoring. Launched in 2014, the IRIS Registry is the nation's first comprehensive eye disease and condition registry and the world's largest specialty clinical data registry. As of April 1, the registry includes nearly 18,000 physicians, 48 million unique patients from all payers contributing 199.6 million patient visits. The Mass. Eye and Ear IRIS Registry Analytics Team -led by co-principal investigators Alice C. Lorch, MD and Joan W. Miller, MD- will involve investigation and partnership with many faculty at Mass. Eye and Ear over the coming years. Other academic groups awarded access include Stanford University, University of Michigan/UCLA/Duke/UNC, University of Washington, and Wills Eye Hospital. FORM 990, PART III, LINE 4B EDUCATION As a Harvard Medical School teaching hospital, Mass. Eye and Ear trains future medical leaders in the fields of ophthalmology and otolaryngology through residency programs, as well as clinical and research fellowships. Department of Otolaryngology 27 Residents 10 Clinical Fellows 81 Research Fellows 3 Research Residents Department of Ophthalmology 24 Residents 26 Clinical Fellows 108 Research Fellows 1 Optometric Resident In other ENT education news, we continue to enjoy our state-of-the-art Otolaryngology Surgical Training Laboratory and have held several major courses there this year. Our department organized its first "Women in Otolaryngology" symposium to discuss the opportunities and challenges of being a woman in a historically male-dominated field. Our panelists included Stacey T. Gray, MD, Margaret A. Kenna, MD, MPH, Konstantina M. Stankovic, MD, PhD, and Sylvette R. Wiener-Vacher, MD, PhD. We held our first annual Mastoid Bowl this summer. Hosted by Daniel J. Lee, MD, FACS, this competition evaluated otolaryngology residents as they performed mastoidectomies on cadavers in the Joseph B. Nadol, Jr., MD, Surgical Training Laboratory. The winner was Chief Resident Katie Phillips, MD. Our year-end graduation lectureship has been officially named the "Joseph B. Nadol, Jr. Lectureship." Dr. Nadol has contributed, and continues to contribute, to the stature and standing of this department in so many ways. Department of Ophthalmology The Mass. Eye and Ear Department of Ophthalmology established the Distinguished Scholar in Ophthalmology. Several Mass. Eye and Ear faculty presented named lectures at the 2018 American Academy of Ophthalmology (AAO) Annual Meeting in October. Joan W. Miller, MD presented the Schepens Award Lecture on AAO Retina Subspecialty Day. Her talk - Developing Therapies for AMD: The Art and Science of Problem-solving - revisited the pathway to successful treatment of age-related macular degeneration, and shared ideas on how to continue innovating in ophthalmology. Dr. Miller's lecture was covered by AAO's ONE Network and Ophthalmology Times, and shared on social media by Retina Today and Retinal Physician, among others. Joseph F. Rizzo III, MD presented the William F. Hoyt Lecture, "Unraveling the enigma of non-arteritic anterior ischemic optic neuropathy." His talk shed light on the most common causes of acute optic nerve injury in people age 50. James Chodosh, MD, MPH presented the Jones/Smolin Lecture, "The persistent enigma of adenovirus keratitis: viral pathogenesis in the cornea," which highlighted clinical signs that differentiate viral keratitis from other etiologies. The 3rd Biennial International Symposium on Ocular Regeneration, held on October 11, brought together leaders in the fields of ophthalmology, bioengineering, and regenerative medicine who aim to accelerate cures for blinding diseases. The David H. Koch Institute Professor, Massachusetts Institute of Technology, presented a talk entitled "Biomaterials and biotechnology: from the discovery of the first angiogenesis inhibitors to the development of controlled drug delivery systems and the foundation of tissue engineering." Organized by Harvard Ophthalmology Ocular Regenerative Medicine Institute Co-Directors Michael Young, PhD and Demetrios Vavvas, MD, PhD, the event was sponsored by RxGen, Alcon, Biogen, Catalyst Biosciences, Gorin Foundation, ReNeuron, and the National Institutes of Health. Held on October 12-13, the 5th Biennial International Symposium on AMD drew more than 200 clinicians, researchers, trainees, and industry representatives who discussed the latest advances in AMD research and the challenges that lay ahead. Franois Delori, PhD, a Harvard Medical School Professor of Ophthalmology and Senior Scientist at Schepens Eye Research Institute of Mass. Eye and Ear, presented the 2018 Ephraim Friedman Lecture, entitled "Fundus autofluorescence." Organized by Harvard Ophthalmology AMD Center of Excellence Co-Directors Patricia D'Amore, PhD, MBA, Ivana Kim, MD, and Deeba Husain, MD, the event was sponsored by the Broadhurst Foundation, Regeneron, Genentech, Biogen, Macular Degeneration Foundation, Heidelberg Engineering, American Macular Degeneration Foundation, Merck, and the National Institutes of Health. |
| Innovation and Interaction Sessions is a new educational initiative |
that brings residents together for one 3-hour block each month to participate in innovative and interactive learning utilizing the Surgical Training Laboratory. The first session on August 3, 2018 was led by Silas Wang, MD and Elizabeth Rossin, MD, PhD. Highlights included practicing setting up and priming the phaco machine, loading 1-piece and 3-piece IOLs, positioning and manipulation of the microscope, paracentesis and main wound construction followed by suturing of wounds, teaching sutures, and learning to load and implant capsular tension rings and 3-piece IOLs. The second session on September 7, 2018 was led by David Hunter, MD, PhD, David Sol-del Valle, MD, Tav van Zyl, MD, and Dr. Rossin. Junior residents participated in a Refraction boot camp where they learned about retinoscopy and refraction. Senior residents participated in a minimally invasive glaucoma surgery (MIGS) workshop where they learned to place an iStent, and having completed this training are now able to participate in MIGS procedures with Dr. Sol-del Valle in the operating room. Resident feedback on these sessions has been very positive. A continuity clinic was created to supplement the continuity in patient care that residents experience in caring for patients within the clinical rotations. In this enhanced continuity experience, residents see patients that they evaluated in the Mass. Eye and Ear Emergency Department (MEE ED) in follow-up appointments. Residents also have the opportunity to participate in surgeries of patients that they initially cared for in the MEE ED. Residents attend continuity clinic approximately 2 half days per month. This clinic is directly supervised by the Mass Eye and Ear Chief Resident, who is a member of the Mass Eye and Ear faculty. Feedback from residents and faculty has been positive. An ophthalmology residency program wellness committee was formed consisting of residents and faculty members. The committee works with the residency program, the department, and the GME efforts to support and encourage activities that promote resident wellness. Examples of early initiatives include revamping the resident room, a space in which the residents have workspaces, lockers, computers, and often spend down-time, as well as organizing a series of resident-faculty social activities outside of work. Mass Eye and Ear has also appointed a resident representative to the Partners Healthcare Resident Wellness Committee. We aim to continue growth of these important initiatives. Awards and Honors Department of Ophthalmology Petr Baranov, PhD: Audacious Goals Initiative for Regenerative Medicine grant, National Eye Institute (in collaboration with Vanderbilt University Medical Center and University of Alabama at Birmingham) Dean Cestari, MD: A. Clifford Barger Excellence in Mentoring Award, Harvard Medical School; Dean's Community Service Award, Harvard Medical School; Surgical Teacher of the Year, Harvard Department of Ophthalmology Han-Ying (Peggy) Chang, MD: Norman Knight Leadership Award, Mass. Eye and Ear Jing Chen, PhD: Special Scholar Award, Research to Prevent Blindness Teresa C. Chen, MD: Senior Achievement Award, American Academy of Ophthalmology James Chodosh, MD, MPH: Jones/Smolin Lecture, American Academy of Ophthalmology Joseph B. Ciolino, MD: Sloan Healthcare Innovation Prize, MIT Patricia A. D'Amore, PhD, MBA: American Academy of the Arts and Sciences Elected Fellow; Barbara J. McNeil Faculty Award for Exceptional Service to HMS/HSDM Reza Dana, MD, MSc, MPH: Friedenwald Award, Association for Research in Vision and Ophthalmology; Stein Innovation Award, Research to Prevent Blindness Mary-Magdalene (Ugo) Dodd, MD: 2018 Fellow Research Award, American Association for Pediatric Ophthalmology and Strabismus Thaddeus Dryja, MD: Helen Keller Prize for Vision Research, BrightFocus and Helen Keller Foundation; Appointed Associate Member of Broad Institute Rosario Fernandez-Godino, PhD, MSc: BrightFocus Foundation Award (for macular degeneration research) Rachel M. Huckfeldt, MD, PhD: Career Development Award, Foundation Fighting Blindness Frederick Jakobiec, MD, DSc: Simmons Lessell Excellence in Education Award, Harvard Ophthalmology; Merrill Reeh Prize, American Society of Ophthalmic Plastic and Reconstructive Surgery John H. Kempen, MD, MPH, MHS, PhD: Dean's Community Service Award, Harvard Medical School Carolyn Kloek, MD: WIO Educators Award, Women in Ophthalmology Wendy Liu, MD: Gragoudas-Folkman Award, Mass. Eye and Ear Gang Luo, MD: Innovations Technology Low Vision Research Award, Research to Prevent Blindness Zhonghui (Katie) Luo, MD, PhD: Dean's Community Service Award, Harvard Medical School Lotfi Merabet, OD, PhD, MPH: A. Clifford Barger Excellence in Mentoring Award, Harvard Medical School Joan W. Miller, MD: Lucien Howe Medal, American Ophthalmological Society*; Gertrude D. Pyron Award and Lecture, American Society of Retina Specialists and Retina Research Foundation*; Charles L. Schepens, MD Award and Lecture, American Academy of Ophthalmology, Retina Research Foundation and Schepens International Society*; Mentor with Distinction, Harvard Medical School (*Dr. Miller is the only individual ever to win all three awards) John B. Miller, MD: Macula Society membership Kareem Moussa, MD: The Robert Brockhurst Academic Development Award, Mass. Eye and Ear Shizuo Mukai, MD: William and Carolyn Aliski Distinguished Scholar in Ophthalmology, Mass. Eye and Ear (inaugural) Eric Yin-Shan Ng, PhD: Young Mentor Award, Harvard Medical School Patrick Oellers, MD: The Thomas J. Madden Fellowship in Retina, Mass. Eye and Ear Billy Xiaoyi Pan, MD: 2017-18 Ruthanne and Richard J. Simmons Glaucoma Fellow, Mass. Eye and Ear Eli Peli, MSc, OD: Harold Amos Faculty Diversity Award, Harvard Medical School Roberto Pineda II, MD: Jos I. Barraquer Lecture and Award, Brazilian International Society of Refractive Surgery Joseph F. Rizzo III, MD: William F. Hoyt Lecture, American Academy of Ophthalmology Miin (Irene) Roh, MD, PhD: Evangelos S. Gragoudas Award, Macula Society Hajirah N. Saeed, MD: Dohlman Fellowship Award, Claes Dohlman Society Magali Saint-Geniez, PhD: Iraty Award for Research in Retinal Diseases, Mass. Eye and Ear Jane Schweitzer, MD: Clinical Teacher of the Year, Harvard Department of Ophthalmology Paolo Antonio S. Silva, MD: AAO Achievement Award, American Academy of Ophthalmology; Macula Society membership Luk Vandenberghe, PhD: Outstanding New Investigator Award, American Society of Gene and Cell Therapy; Appointed Associate Member of Broad Institute Janey Wiggs, MD, PhD: Elected to the National Academy of Medicine; Dr. David L. Epstein Award, ARVO Foundation (with mentee Ryan Collantes, MD) Yoshihiro Yonekawa: Achievement Award, American Academy of Ophthalmology |
| Department of Otolaryngology |
Dunia Abdul-Aziz, MD, was the recipient of the 2017 Yellen Young Investigator Award. This award is made possible by the generosity of Mass. Eye and Ear Trustees, Patricia and Barry Yellen. Daniel G. Deschler, MD, FACS, and Marlene L. Durand, MD, published a new textbook, Infections of the Ears, Nose, Throat, and Sinuses. Dr. Deschler was also appointed chair of the Patient Care Division of the American Head and Neck Society. Kevin S. Emerick, MD, is the recipient of the 2018 Chris O'Brien Traveling Fellowship, which is presented by The Research and Education Foundation of the American Head and Neck Society. Allen Feng, MD, and Sid Puram, MD, PhD, were the co-recipients of the 2018 Triological Society (Eastern Section)'s William W. Montgomery, MD Resident Research Award for their abstract, "Intraoperative recurrent laryngeal nerve monitoring during thyroid surgery: Trends among otolaryngologists and general surgeons." Tessa A. Hadlock, MD, was re-elected as president of the International Sir Charles Bell Society. Eric H. Holbrook, MD, joined the American Rhinologic Society Board of Directors. Judith S. Kempfle, MD, won the poster blitz contest at the 2018 Association for Research in Otolaryngology annual meeting. Elliott D. Kozin, MD, was named a 2018 Star Reviewer for the journal Otolaryngology-Head and Neck Surgery. Robin W. Lindsay, MD, was named co-chair of the American Academy of Facial Plastic and Reconstructive Surgery Meeting at the Combined Otolaryngology Spring Meetings and chair of the WIO Research and Survey Committee for the American Academy of Otolaryngology-Head and Neck Surgery. Gregory W. Randolph, MD, FACS, FACE, has been elected chair of the Endocrine Surgery Section of the American Head and Neck Society. Steven D. Rauch, MD, received an honorary professorship at the Annual Vestibular Conference of the Guangdong Academy of Medical Sciences in Guangzhou, China. He was also appointed as a member of the Mnire's Disease Advisory Board of the Hearing Health Foundation. Ahmad R. Sedaghat, MD, PhD, was the recipient of the 2018 Eleanor and Miles Shore Fellowship Program Award for Scholars in Medicine. Mark G. Shrime, MD, MPH, PhD, FACS, was awarded the 2018 Arnold P. Gold Foundation Award for Humanism in Medicine by the American Academy of Otolaryngology-Head and Neck Surgery. Kristina Simonyan, MD, PhD, Dr med, was invited to serve on the Scientific Advisory Board of the Tourette Association of America. Department of Anesthesiology Iuliu Fat, MD: MEE/HMS Department of Anesthesia: Excellence in Teaching Award Department of Radiology MEE Radiology Department: 52nd ASHNR Annual Meeting, First Place for Best Scientific Electronic Exhibit Dr. Amy Juliano: RSNA International Visiting Professor Dr. Katherine Reinshagen: Promoted to Associate Staff Radiologist Form 990, Part III, Line 4c Facilities, Equipment and Technology Department of Ophthalmology Mass. Eye and Ear launched a unique emergency department (ED) and inpatient consultation service, known as the Ophthalmology Hospitalist Program. Senior credentialed ophthalmologists now provide consults for patients admitted to general hospitals, including Mass General, Brigham and Women's Hospital, and Faulkner Hospital. The program fortifies connections among Harvard Ophthalmology hospital affiliates, and enhances trainee education and the existing consult service at Mass. Eye and Ear. Members of the hospitalist program include Jane Schweitzer, MD, Jo-Ann Haney-Tilton, MD, FACS, EMHL, and Aisha Traish, MD. The refractive and laser vision correction services moved to Mass. Eye and Ear's Waltham patient care site in November, 2018. Mass. Eye and Ear now offers a new type of minimally-invasive laser vision correction, the ReLEx SMILE procedure for the treatment of myopia (nearsightedness) at its Waltham location. Mass. Eye and Ear specialists are among the most experienced with the SMILEapproach nationwide, and the first in New England to offer the procedure. A new collaborative program between Mass. Eye and Ear and Mass General Hospital offers mental health services to patients within the Eye Trauma Service at Mass. Eye and Ear. The program allows visits with a psychologist for patients with severe trauma to their eye or face, including loss of an eye, loss of vision, or disfigurement. This service is intended to assist a patient in his or her initial adjustment to injuries and can also facilitate referral to a mental health care provider should the patient require ongoing care. Department of Otolaryngology Mass. Eye and Ear expanded to the Cape, opening two otolaryngology practices: Mass. Eye and Ear, Harwich Mass. Eye and Ear, Mashpee Began the Weymouth office build-out to accommodate more patients Began 11th floor renovation of clinic and office spaces Increased ambulatory space in Head and Neck Updated Head and Neck space aesthetics Built workstations for Head and Neck PAs Started building out phlebotomy and EKG Renovated Medical Evaluation Center (MEC) to accommodate Laryngology clinics Added huddle space for family conferences in Laryngology Completed build-out of the Surgical Photonics Engineering and Laboratory (SPEL) Department of Anesthesiology 2 Nihon Kohden Patient Monitors 2 Nihon Kohden Multi-Gas Analyzers 4 Glidescopes 1 Draeger Anesthesia MRI Machine 1 Sonosite Portable Ultrasound Machine 2 Norm-O-Temp Warming Systems Department of Radiology Installed a second 3.0T MRI with state-of-the-art audio/visual enhancements to provide a superior patient experience and advanced software to leverage and explore new and novel imaging techniques Planned the replacement of the department's fluoroscopy machine (used to examine patients with a variety of voice, speech, airway and swallowing disorders) with a state of the art unit that significantly reduces the amount of radiation exposure for patients and staff Community Engagement Department of Ophthalmology October 11, 2017 and September 13, 2018: Presidents Lecture Series November 30, 2017: Neighborhood House Charter School Vision Screenings Spring 2018: Fenway High School Interns April 4, 2018: Roxbury Tenants of Harvard Open House at Longwood April 7, 2018: Stoneham Chamber of Commerce 2018 Health and Wellness Expo May 17, 2018: Graves' Disease Public Forum July 19 and August 9, 2018: Camp Harbor View Vision Screenings Department of Otolaryngology Michael S. Cohen, MD, sent earmuff-style hearing protection to the New England Patriots players for their kids to wear during the Super Bowl. He also hosted his annual Hearing Center Family Carnival, which brings dozens of patient families to Mass. Eye and Ear for a day of fun. Aaron K. Remenschneider, MD, MPH, and Alicia M. Quesnel, MD, are working with the Massachusetts Commission for the Deaf and Hard of Hearing on continued support for the Boston Marathon bombing victims. They have established a formal collaboration with them to serve and support survivors, and collect clinical outcomes data on patients who are local. Led by Mark A. Varvares, MD, FACS, a team of volunteers held head and neck screenings at the Mission Hill Health Fair, where they screened more than 30 people. The Mass. Eye and Ear Department of Audiology sponsored a team for the Walk 4 Hearing, which benefits the Hearing Loss Association of America. In addition to the accomplishments highlighted in this report, Mass. Eye and Ear was proud to be named Employer of the Year by the Massachusetts Commission for the Blind. |
| FORM 990, PART VI, LINE 1A |
THE INFIRMARY'S BYLAWS STATE THE FOLLOWING: THERE SHALL BE AN EXECUTIVE COMMITTEE CONSISTING OF THOSE INDIVIDUALS WHO ARE SERVING AS MEMBERS OF THE EXECUTIVE COMMITTEE OF THE MEMBER. THE EXECUTIVE COMMITTEE SHALL HAVE THE POWER TO TRANSACT ALL EMERGENCY BUSINESS OF THE CORPORATION DURING THE PERIOD BETWEEN THE MEETINGS OF THE BOARD OF DIRECTORS. THE EXECUTIVE COMMITTEE SHALL ALSO TRANSACT SUCH BUSINESS, PERFORM SUCH DUTIES, AND EXERCISE SUCH POWERS AS MAY BE DIRECTED OR DELEGATED BY THE BOARD OF DIRECTORS FROM TME TO TIME. THE EXECUTIVE COMMITTEE SHALL KEEP A RECORD OF ITS PROCEEDINGS. ALL ACTIONS OF THE EXECUTIVE COMMITTEE SHALL BE REPORTED TO THE BOARD OF DIRECTORS AT ITS NEXT REGULAR MEETING. FORM 990, PART VI, LINE 6 The Foundation is the sole member of the Infirmary. Effective April 1, 2018, Partners Healthcare System, Inc.(Partners) became the sole member of the Foundation. As a result the Foundation and its affiliated entities became part of the comprehensive, integrated healthcare system organized and operated by Partners that includes hospitals, physicians, charitable, scientific, educational, research and other Partners affiliated organizations. |
| FORM 990, PART VI, LINE 7A |
THE GOVERNOR OF THE COMMONWEALTH HAS THE AUTHORITY TO APPOINT TWO DIRECTORS. THE BYLAWS OF THE INFIRMARY STATE THAT THE REMAINING DIRECTORS ARE THOSE INDIVIDUALS SERVING AS DIRECTORS OF ITS SOLE MEMBER, THE FOUNDATION OF THE MASSACHUSETTS EYE AND EAR INFIRMARY, INC. ("THE FOUNDATION"). FORM 990, PART VI, LINE 7B THE FOUNDATION IS THE SOLE MEMBER OF THE INFIRMARY AND RETAINS THE AUTHORITY TO MAKE DECISIONS REGARDING THE INFIRMARY. FORM 990, PART VI, LINE 11B THE INFIRMARY'S FORM 990 IS PREPARED BY PRICEWATERHOUSECOOPERS, LLP USING INFORMATION PREPARED BY MANAGEMENT. AFTER THE FORM 990 IS COMPLETED, IT IS REVIEWED BY THE MANAGER OF INVESTMENTS AND FOUNDATION ACCOUNTING. THE FORM 990 IS THEN PRESENTED TO THE FINANCE COMMITTEE FOR REVIEW AND APPROVAL AS AUTHORIZED BY THE BOARD OF DIRECTORS. THE BOARD OF DIRECTORS ARE ALSO GIVEN THE FORM 990 FOR REVIEW WITH TIME TO SUBMIT COMMENTS AND QUESTIONS BEFORE FINAL FILING. FORM 990, PART VI, LINE 12C MEMBERS OF THE STAFF ARE REQUIRED TO DISCLOSE CONFLICTS OF INTEREST TO THEIR CHIEF OF SERVICE OR DEPARTMENT AND DIRECTOR OF LABORATORY/UNIT. MEMBERS OF THE BOARD OF DIRECTORS ARE REQUIRED TO DISCLOSE ANNUALLY, IN WRITING, ANY INTERESTS THAT COULD GIVE RISE TO CONFLICTS. THE OFFICE OF THE INTERNAL LEGAL COUNSEL OBTAINS AND REVIEWS THE ANNUAL CONFLICTS OF INTEREST STATEMENTS SUBMITTED BY MEMBERS OF THE BOARD OF DIRECTORS, AND REPORTS ON THE SAME TO THE AUDIT AND COMPLIANCE COMMITTEE OF THE BOARD. WITH RESPECT TO INTERESTS DISCLOSED BY BOARD MEMBERS THAT COULD GIVE RISE TO CONFLICTS OF INTEREST, THE INTERNAL LEGAL COUNSEL REVIEWS ALL TRANSACTIONS BETWEEN SUCH INTERESTS AND AFFILIATES OF THE INFIRMARY, TO DETERMINE WHETHER THESE TRANSACTIONS WERE CONDUCTED AT ARM'S LENGTH. FORM 990, PART VI, LINE 15 THE CHAIRMAN OF THE COMPENSATION COMMITTEE OF THE BOARD OF THE INFIRMARY PRESENTS A RECOMMENDATION TO THE COMPENSATION COMMITTEE WHO HAVE FINAL APPROVAL OF THE CEO'S BASE SALARY AND BONUS AMOUNT. THE CEO RECOMMENDS THE SALARIES OF THE CHIEFS AND VICE PRESIDENTS TO THE COMPENSATION COMMITTEE OF THE BOARD WHO HAS FINAL AUTHORIZATION TO APPROVE IT. COMPENSATION OF THOSE AT THE DIRECTOR LEVEL, INCLUDING THE DIRECTOR OF PROFESSIONAL REVENUE CYCLE, DIRECTOR OF FACILITIES PLANNING, AND CHIEF INFORMATION OFFICER IS REVIEWED AND APPROVED BY THE VICE PRESIDENT OF OPERATIONS. THE COMPENSATION COMMITTEE MEETING WAS HELD ON NOVEMBER 15, 2017. TOTAL COMPENSATION FOR THE CEO, CHIEFS AND VICE PRESIDENTS, INCLUDING BONUS PAYMENTS, INCLUDING COMPARABILITY DATA, IS ANALYZED BY INDEPENDENT COMPENSATION CONSULTANTS AND IS DETERMINED TO BE REASONABLE. |
| FORM 990, PART VI, LINE 19 |
SUMMARIZED FINANCIAL STATEMENTS ARE AVAILABLE ON THE INFIRMARY'S WEBSITE: WWW.MASSEYEANDEAR.ORG. AUDITED FINANCIAL STATEMENTS ARE AVAILABLE UPON REQUEST. THE INFIRMARY'S GOVERNING DOCUMENTS AND FORM 990 ARE AVAILABLE UPON REQUEST. THE CONFLICT OF INTEREST POLICY IS ALSO AVAILABLE UPON REQUEST. |
| FORM 990, PART XI, LINE 9 |
OTHER CHANGES IN NET ASSETS OR FUND BALANCES: ADJUSTMENT FOR PENSION AND POSTRETIREMENT RELATED CHANGES OTHER THAN NET PERIODIC PENSION COST: $13,940,727 |
Attach to Form 990 or Form 990-EZ. 
Attach to Form 990 or 990-EZ.